Teva Establishes Four Pillars To Prop Up Its Return-To-Growth Strategy

Austedo And Uzedy Key To Near-Term Growth

New CEO Richard Francis outlined the company’s new focus on innovative brands, funded by a portion of capital reallocated from Teva’s generics business.

Four massive columns, blue sky in Barcelona of Spain
Teva's growth pillars will support innovation over generics • Source: Shutterstock

Teva Pharmaceutical Industries Ltd. – a company best known for selling generic drugs – said it will pivot more towards innovative drugs in the future as the headwinds for generic drugs continue to mount.

Teva has been struggling to increase revenue since 2017 but has a new strategy for growth over the next five...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip